Aldeyra Therapeutics Inc (STU:137)
€ 5.158 0.084 (1.66%) Market Cap: 303.87 Mil Enterprise Value: 206.88 Mil PE Ratio: 0 PB Ratio: 3.34 GF Score: 40/100

Q4 2018 Aldeyra Therapeutics Inc Earnings Call Transcript

Mar 08, 2019 / 01:00PM GMT
Release Date Price: €6.61 (-4.20%)
Operator

Good morning, and welcome to the Aldeyra Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions) Please note, this event is being recorded.

I now will turn the call over to Joshua Reed, please go ahead.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Good morning, everyone. I'm Joshua Reed, Chief Financial Officer of Aldeyra Therapeutics, and welcome to the Aldeyra Therapeutics conference call to discuss our year-end 2018 financial results. With me today is Dr. Todd Brady, Chief Executive Officer of Aldeyra Therapeutics.

This conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans, research, development and commercial plans or expectations, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot